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Introduction 
 
The essentiality of NAD+-dependent processes in fuel utilization, 
gene regulation, DNA repair, protein modification, and cell signaling 
events makes the analysis of NAD+ metabolites central to an 
understanding of what a tissue is doing. NAD+ is the key hydride 
transfer coenzyme for a wide variety of oxidoreductases and is also the 
consumed substrate of sirtuins, poly adenosine diphosphate ribose 
(ADPr) polymerase, mono ADPr transferases, and cyclic ADPr 
synthases [1,2]. Measurement of NAD+ and related metabolites 
including several nucleosides and nucleotides (hereafter, the NAD+ 
metabolome) serves as a powerful indicator of the ability of a cell or 
tissue to perform processes such as glycolysis, gluconeogenesis, fatty 
acid oxidation, reactive oxygen species detoxification, among others. 
Moreover, the state of the NAD+ metabolome can serve as an 
indication of nutrition, health and disease. 
Because NAD+ and related metabolites vary in cellular 
concentration from ~1 µM to ~1 mM, the analytical procedure must 
be robust, reproducible, and rapid. Liquid chromatography (LC)-
based assays afford the ability to measure multiple metabolites in a 
timely fashion with the duration of each run ranging from 10 minutes 
to an hour.  However, quantification through HPLC-UV-Vis 
methods is severely compromised based on the complexity of samples.  
In complex mixtures, a single peak may contain the metabolite of 
interest in addition to many other metabolites of identical retention 
time.  In addition, peak shapes are rarely unaffected by complexity.  
Some investigators use a UV-vis signal at a retention time as the 
primary means for identification of a metabolite of interest—
collected fractions are then subjected to mass spectrometry to confirm 
(nonquantitatively) the presence of the metabolite. This process leaves 
a great deal of data in the dark.  Because every NAD+  metabolite can  
 
 
 
 
 
 
 
 
 
be converted to one or more other metabolites, snapshots of the levels 
of NAD+ , nicotinamide (Nam) or any other NAD+  metabolite 
without assessment of the NAD+ metabolome on a common scale has 
the potential to be misleading. 
Because of its specificity and sensitivity, LC coupled to mass 
spectrometry (LC-MS) is a leading analytical method in the 
measurement of small molecules in complex samples.  As with HPLC-
UV-vis methods, LC serves to separate compounds of interest and 
must be optimized in the same way as any HPLC method.  Because all 
LC-MS data contain at least two dimensions of data (retention time 
plus the mass:charge ratio, termed m/z), LC-MS increases specificity 
with respect to LC-UV-vis methods that report complex absorbance 
spectra as a function of retention time or matrix-assisted laser 
desorption ionization (MALDI)-based methods that report complex 
m/z data without retention times.  Multidimensional MS, i.e., LC-
MSn, provides further information because a particular analyte breaks 
down to component ions at a particular ionization energy.  An ideal 
LC-MS method identifies an optimal extraction and separation 
method for all molecules of interest, detects the compounds in either 
negative or positive ion mode MS, and has sufficient LC separation to 
subject each molecule of interest to MSn analysis.  The method is then 
a series of selective reaction monitoring (SRM) protocols in which 
analytes are identified and quantified by MS as they come off the LC. 
Whereas metabolomic discovery projects require high mass 
resolution instruments, targeted quantitative LC-MS assays can make 
use of lower resolution tandem mass spectrometers such as triple 
quadrupoles (QQQ). Here, the multidimensional data (retention 
time, m/z, and MS2 transitions) are used to distinguish closely related 
metabolites, such as NAD+ from NADH.  Limits of quantification in 
optimized targeted, quantitative LC-MS assays are in the femtomole 
range. 
Though mass spectrometers offer great analytical power for 
measuring the NAD+ metabolome, they also present technical 
challenges not encountered in other analytical techniques.  These 
challenges include development of optimal mass spectrometry 
conditions, proper separation of metabolites, and the best choice of 
internal standards.  Here we discuss NAD+ metabolism and describe 
an optimized LC-MS2 assay of the NAD+ metabolome. 
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NAD+ Transactions 
 
In fungi and vertebrates, NAD+ concentration is maintained by 
either de novo synthesis from tryptophan [4] or through salvage of 
nicotinic acid (NA) [5], nicotinamide (Nam) [6], and the recently 
identified NAD+ precursor vitamin, nicotinamide riboside (NR) [7] 
(Figure 1).  Some organisms, such as Candida glabrata, lack de novo 
synthesis [8].  Many vertebrate cell types turn this pathway off [2].  
De novo synthesis proceeds from tryptophan in six steps to produce 
nicotinic acid mononucleotide (NAMN) and in two additional steps 
to produce NAD+.  When NAD+ is the substrate of an enzyme such 
as glyceraldehyde phosphate dehydrogenase (GAPDH), fuel oxidation 
reactions will reduce NAD+ to NADH.  In the case of GAPDH, the 
reaction is reversible, such that NADH is reoxidized to NAD+ in the 
gluconeogenic direction.  NAD+ and NADH can be phosphorylated 
to NADP+ and NADPH.  NADP+ is required for the pentose 
phosphate pathway (PPP), which produces NADPH.  NADPH is 
required for detoxification of reactive oxygen species and reductive 
biosynthesis of lipids and steroids.  Just as glucose-6-phosphate 
oxidation by the PPP produces NADPH, glutathione reactivation and 
reductive biosynthesis reoxidizes NADPH to NADP+. 
Beyond serving as a coenzyme in hydride reactions, NAD+ is a 
consumed substrate for enzymes such as sirtuins, PARPs, and other 
ADPr transfer enzymes [1,2,9,10]. Though CD38 has an activity on 
NADP+, at least in vitro [11], the typical activity of an NAD+-
consuming enzyme involves NAD+ as the substrate, and products that 
include Nam and an NAD+-derived ADPr moiety.  Thus, to sustain 
intracellular NAD+ levels, actions of NAD+-consuming enzymes must 
be accompanied by Nam salvage [1,2].  Nam salvage differs between 
fungi and vertebrates.  In fungi, Nam is hydrolyzed by the PNC1-
encoded nicotinamidase to NA [6].  NA is then converted by the first 
enzyme of the Preiss-Handler pathway, the NPT1-encoded NA 
phosphoribosyltransferase, to form NAMN.  The second and third 
steps of Preiss-Handler salvage correspond to the final two steps of de 
novo synthesis, whose last step is glutamine-dependent NAD+ 
synthetase [12].  In vertebrates, Nam produced as a product of 
NAD+-consuming enzymes cannot be salvaged as NA intracellularly.  
However, if Nam goes through the gut, bacterial nicotinamidases 
produce NA [13], which circulates and is used via Preiss-Handler 
salvage. 
Intracellular Nam salvage in vertebrates depends on a Nam 
phosphoribosyltranferase, which entered the scientific literature with 
the names pre-B cell colony enhancing factor (PBEF) [14] and 
Visfatin [15].  Now termed Nampt, this protein is widely expressed 
as an intracellular enzyme and also circulates as an active extracellular 
molecule [16,17].  First predicted to be part of a partially extracellular 
NAD+ biosynthetic cycle [1] along with CD73, a homolog of 
bacterial NMN 5’-nucleotidase, extracellular Nampt clearly has 
enzymatic activity [17].  However, extracellular NMN remains 
controversial in part due to deficiencies in NAD+ metabolite 
quantification.  As a phosphoribosyltransferase, Nampt activity 
depends on phosphoribosyl pyrophosphate (PRPP), an extracellular 
source of which has not been demonstrated [18].  By an HPLC-UV 
method, which may have been distorted by co-eluting analytes, the 
abundance of extracellular NMN was reported to be 80 µM [17].  
However, using LC- MSn, it was reported that PRPP and NMN are 
virtually absent and, moreover, are unstable in mouse plasma [18].  It 
stands to reason that extracellular Nampt may have activity in local 
environments and developmental/nutritional conditions in which the 
substrates, Nam and PRPP, and the ATP activator are at substantial 
levels.  Systemic NMN at 80 µM appears to be implausible, however. 
Nam and NA can also be methylated, which would be predicted 
to block salvage.  In plants, NA N-methyltransferase produces a 
compound known as trigonelline by transfer of the methyl group 
Figure 1. NAD+ Biosynthesis in yeast and vertebrates. Intracellular NAD+ is derived from either de novo synthesis from tryptophan or from salvage of NA, Nam, 
or NR. In yeast, Nam is converted to NA by nicotinamidase Pnc1p (dotted line).  In yeast and vertebrates, NA is phosphoribosylated to NAMN, an intermediate 
in de novo synthesis, and converted to NAD+ by way of NAAD in a step catalyzed by glutamine-dependent NAD+ synthetase [12].  In vertebrates, Nam 
conversion to NMN is catalyzed by Nampt [16].  The other source of NMN in yeast and vertebrates is phosphorylation of NR by NR kinases.  NR and NAR can be 
split to the corresponding pyridine bases.  NAR phosphorylation yields NAMN.  NMN is converted to NAD+ by NMN adenylyltransferase activity, which is 
reversible.  As shown, in vertebrates, NMN must be imported into mitochondria for conversion to NAD+.  Enzymatic NAD+ and NADP+ consumption releases the 
Nam moiety and produces ADPr products.  Finally, Nam and NA can be converted to non-salvageable products. 
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from S-adenosyl-methionine [19,20].  The corresponding Nam N-
methyltransferase (NNMT) has been well characterized in vertebrates 
[21].  Increased NNMT expression has been observed in Parkinson’s 
Disease [22] with a potential role in disease etiology [23,24].  
NNMT is also increased in malignancy [25] and plays an apparent 
role in cell migration [26].  Despite the reported roles in disease, N-
methyl Nam (NMNam) is a natural metabolite in healthy individuals 
with reported antithrombotic [27] and vasorelaxant [28] activities 
that is increased in plasma and urine after endurance exercise [29].  
NMNam is ultimately converted to N1-Methyl-2-pyridone-5-
carboxamide and N1-Methyl-4-pyridone-5-carboxamide. 
Though the primary breakdown product of NAD+ is Nam and 
the complete bacterially digested product is NA, nicotinamide 
riboside (NR) is an additional salvageable precursor that exists 
intracellularly and in milk [3,7,30]. The unique NR salvage pathway 
is via nicotinamide riboside kinases [7]. In addition, NR can be split 
into a Nam moiety and resynthesized to NAD+ via Nam salvage 
enzymes [31].  Nicotinic acid riboside (NAR) is an alternate 
substrate of nicotinamide riboside kinases [32] and purine nucleoside 
phosphorylase [13] that has been shown to be an intracellular NAD+ 
precursor [30] but has not been reported to circulate. 
Whereas NA is the salvageable precursor of NAD+ that has been 
exposed to the most digestive enzymes and Nam is the salvageable 
precursor that is produced by every cell with NAD+-consuming 
enzymes, the main source of dietary NR is probably partial digestion 
of NAD+.  Depending on one’s nutrition and potentially one’s 
microbiome, the three vitamin precursors of NAD+ (NA, Nam and 
NR) and trp should be in circulation [2].  The existence of 
extracellular enzymes with the potential to produce and consume 
NMN, and which consume NAD+, suggests the circulation of 
pyridine nucleotides [1].  Moreover, NMN supplementation of mice 
on high fat diet (HFD) increases insulin sensitivity, glucose tolerance, 
and intracellular NAD+ compared to non-treated mice on the same 
diet [33].  Though extracellular NMN was interpreted to function via 
direct incorporation of the nucleotide into cells [33], careful 
examination indicates that extracellular NA, Nam, and NR increase 
intracellular NAD+ in yeast and vertebrate cells, whereas NMN 
requires dephosphorylation to NR [34].  Consistent with the 
prediction that the ectoenzyme CD73 has NMN 5’-nucleotidase 
activity [1], CD73 has the requisite biochemical activity to catalyze 
NMN dephosphorylation [35].  In the yeast system, NR extends 
replicative longevity in a manner that depends on conversion to 
NAD+ [31].  In mice on high fat diet, NR improves glucose control 
and insulin sensitivity, while moderating the observed increase in 
adiposity [36]. 
In addition to the major difference in Nam salvage between 
vertebrate and yeast systems, there is a mitochondrial 
compartmentalization problem in vertebrates.  In yeast, transporters 
Ndt1 and Ndt2 carry NAD+ across the mitochondrial inner 
membrane [37] and the only mitochondrial NAD+ biosynthetic 
enzyme is NADH kinase, Pos5 [38].  However, in vertebrate cells, the 
nucleocytoplasm and the mitochondrial matrix constitute distinct 
pools of NAD+, NADH, NADP+ and NADPH owing to 
impermeability of the mitochondrial inner membrane to these 
compounds.  Though systems such as the malate-aspartate shuttle and 
nicotinamide nucleotide transhydrogenase transfer reducing 
equivalents across mitochondrial membranes, vertebrate mitochondria 
require a system to import an NAD+ precursor into the matrix for 
conversion to NAD+.  On the basis of localization of NAD+ 
biosynthetic enzymes, that precursor is NMN [34].  Nmnat3, which 
converts NMN to NAD+, is localized to the mitochondrial matrix.  
Nmnat3 is one of three vertebrate NAMN/NMN 
adenylyltranferases—the other two are localized in the nucleus and on 
the cytosolic face of Golgi.  Though one could argue that the ability 
of Nmnat3 to convert NAMN to NAAD suggests that NAMN or 
NMN could be the mitochondrial NAD+ precursor, the NAAD 
product of the NAMN reaction requires glutamine-dependent NAD+ 
synthetase for conversion to NAD+.  Glutamine-dependent NAD+ 
synthetase is not mitochondrially localized [34]. 
As shown in Figure 1, the implication of NMN as the limiting 
precursor for vertebrate mitochondrial NAD+ biosynthesis is 
profound.  De novo synthesis and NA-dependent Preiss-Handler 
synthesis can only supply mitochondria with NAD+ by 
nucleocytosolic conversion to NAD+ followed by the pyrophosphate-
dependent conversion of NAD+ to NMN in a back reaction of 
Nmnat first demonstrated by Arthur Kornberg in 1948 [39] or by 
conversion of NAD+ to Nam and subsequent conversion of Nam to 
NMN.  In contrast, Nam and NR can be converted directly to NMN 
by Nampt and NR kinases, respectively. 
In mitochondria that are burning fuel, the redox reactions are 
largely directional because fuel oxidation converts NAD+ to NADH 
and complex I of the electron transfer chain reoxidizes NADH to 
NAD+. Three vertebrate sirtuins, Sirt3-5, reside in mitochondria, 
where they consume NAD+ in reactions that either modify proteins or 
relieve protein modifications [40]. For the mitochondrial sirtuins to 
work and avoid robbing redox enzymes of NAD+, NMN must be 
imported from the cytosol. 
Completing the major NAD+ transactions, yeast possess two 
cytosolic NAD+/NADH kinases and the mitochondrial NADH 
kinase, Pos5 [38].  Vertebrate cytosolic NAD+/NADH kinase is 
related to the yeast enzymes [41], whereas the vertebrate 
mitochondrial NAD+/NADH kinase was recently identified as a 
homolog of A. thaliana Nadk3, which can use ATP or polyphosphate 
as the phosphate donor [42]. 
 
Quantitative NAD+ Metabolomics 
 
The NAD+ metabolome, as defined here, includes dinucleotides, 
nucleotides, nucleosides, nucleobases and related compounds (Table 
1).  The masses of many of the analytes differ by a single Dalton, 
necessitating optimal separation and careful MS.  The current method 
is an improvement over methods, which measured only select 
metabolites [17,43], and more recent methods, which embraced a 
more complete set of metabolites, but which lacked resolution of 
several compounds [3,44].  Here we review optimization of all 
parameters and a solution to the ionization suppression problem that 
plagued previous methods.   
 
Methods that do not inactivate enzymatic activities upon cell lysis 
[44] are clearly flawed and, based upon the amount of time of sample 
autolysis, cellular NAD+ can be degraded to ~1% of expected values 
(~10 µM) with elevation of apparent NR concentration to ~100 
times expected values (1 mM) [45].  The preferred method of 
extraction is to use boiled, buffered ethanol [46], which is well 
validated for NAD+ metabolites [3,30]. 
For yeast samples, an ideal cell number is 2 to 4.5 x 107, the 
midrange of which can be obtained by harvesting 25 ml of cells at an 
OD600 nm of 0.7.  For mammalian cell culture, we typically use 4 to 20 
x 106 cells, depending upon the cell type.  Yeast cell pellets are 
extracted directly.  Mammalian cell pellets are washed once in ice-cold 
potassium buffered saline.  Cells are resuspended in 300 µL of a 75% 
ethanol/25% 10 mM HEPES, pH 7.1 v/v (buffered ethanol) 
solution, preheated to 80 °C.  Samples are shaken at 1000 rpm in an 
80 °C block for three minutes.  Soluble metabolites are separated 
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from particulate by refrigerated microcentrifugation (10 min, 16kg).  
Though the ethanol-soluble extract contains all the metabolites of 
interest, the weight of the particulate can be used to determine the 
optimized resuspension volume for dried metabolites.  Thus, both the 
particulate and soluble metabolites are dried by speed vacuum at 40 
°C. 
Empirically, we determined that 3.6 mg of yeast or mammalian 
cell-derived particulate corresponds to a metabolite pellet, which can 
be resuspended in a 100 µl volume and produce the desired 
absorbance and LC-MS signals.  Thus, the dry weight of each pellet is 
recorded, divided by 3.6 mg, and multiplied by 100 µl to obtain the 
initial resuspension volume.  Extracts are resuspended in 1% (v/v) 
acetic acid adjusted to pH 9 with ammonium hydroxide (ammonium 
acetate buffer).  These conditions were chosen to preserve NADH 
and NADPH prior to analysis [47]. 
Resuspended metabolites (2 µl) are checked in a Nanodrop 
(ThermoFisher) to determine the OD260 nm, which is typically greater 
than or equal to 14.  The remaining volume is diluted to an OD260 nm 
of 14 in ammonium acetate buffer to obtain the final resuspension 
volume.  For LC-MS, this material is diluted two-fold into two 
different metabolite standards and 2.5 µl of the resulting material is 
injected and analyzed.  Because these dilutions convert the total 
intracellular volume into a known volume of which an effective 
volume of 1.25 µl is analyzed, it is straightforward to calculate the 
intracellular volume of cells under analysis. 
The calculation of intracellular volume is as follows.  For yeast 
cells, the intracellular volume of a single cell is taken as 70 fl [48].  
Thus, the calculated intracellular volume is obtained as 70 fl times the 
cell number.  For mammalian cells, we use 2.5 pl as volume of a HeLa 
cell [49] and calculate the total extracted intracellular volume in the 
same way as for yeast cells.  For example, an extraction of 3 x 107 
yeast cells has a calculated intracellular volume of 2.1 µl.  If this 
sample were resuspended into 100 µl and require no further 
adjustment after checking on the Nanodrop, the 1.25 µl of cell extract 
in a 2.5 µl injection would represent 1.25% of 2.1 µl = 26 nl.  
Because the internal standards permit metabolites to be quantified on 
a mol scale, intracellular metabolite concentrations are determined, in 
this example, as mol of metabolite divided by 2.6 x 10-8 l. 
 
Ionization suppression is the tendency for sample components to 
dampen the ionization and detectability of particular analytes.  Thus, 
one cannot reliably depend on the peak height or area of a metabolite 
in a standard curve of purified metabolites to be on the same scale as 
its peak size in a complex mixture.  In the most advanced previous 
quantification method for NAD+ metabolites, ionization suppression 
was a problem for NAD+, inosine and NA [3]. 
Two internal standard sets are employed.  One set is used to 
quantify 16 metabolites (all analytes except NR, Nam, and NA) and 
is used in an alkaline separation.  The other set is used to quantify 
NR, Nam, and NA in an acidic separation. 
For analytes in the alkaline separation, an extract of Fleischmann’s 
yeast metabolites is prepared from cells grown in 99% uniformly 
labeled 13C glucose (Icon Isotopes, Summit, New Jersey).  In the 
course of this culture, the PPP converts 13C glucose to 13C ribose-5-
phosphate, such that all of the cells’ nucleic acids, mononucleotides 
and dinucleotides incorporate 13C.  Mononucleotides incorporate 5 
additional Da from one ribosyl moeity, whereas dinucleotides 
incorporate 10 additional Da from two ribosyl moeities.  Complete 
incorporation is achieved by growing two serial starter cultures in 13C 
glucose synthetic dextrose complete media, followed by inoculation of 
a 250 ml volume of 13C glucose media at a starting OD600 of 0.2 and 
growth to OD600 of 0.8.  Cells in 50 ml aliquots are then pelleted and 
stored at -80 °C prior to extraction with 300 µl buffered ethanol 
solution. Metabolites are resuspended in 100 µl of the ammonium 
acetate buffer and have a typical OD260 nM of 100.  For LC-MS, 
Fleischmann’s extract is diluted 1:40 into ammonium acetate buffer.  
This diluted Fleischmann’s extract is further diluted 1:1 with 
experimental samples.  In the LC-MS analysis, 2.5 µl of the fully 
diluted material is injected.  This material represents 1.25 µl of the 
experimental extract and an appropriate amount of Fleischmann’s 
extract for metabolite quantification.  
Because the vitamins Nam and NA do not contain a carbohydrate 
group, they are not labeled by heavy labeled glucose and require the 
second set of internal standards for accurate quantification.  To each 
sample or standard solution, heavy labeled Nam and NR are added 
such that the final concentration is 1.5 µM.  18O labeled Nam is 
prepared by tetramethylguanidine- catalyzed hydrolysis with 3-cyano-
pyridine and H218O, as described [50].  Though heavy NR is present 
in the Fleischmann’s yeast extract standard, NR is best separated and 
quantified in an acidic separation with Nam and NA.  Heavy labeled 
NR is made as described [51]. 
We prepare stock solutions (typically at 10 mM) of each 
metabolite to be quantified and then prepare a set of standard 
solutions containing the whole set of metabolites to be quantified at a 
range of concentrations (0, 0.1, 0.2, 0.6, 2, 6, 20, 60, and 200 µM).  
For the alkaline separation, these standards are mixed 1:1 with the 
1:40 dilution of Fleischmann’s extract so that each quantifiable 
metabolite in the extract can be set to a pmol amount.  For example, if 
a particular metabolite in the Fleischmann’s sample were to 
interpolate precisely between the 2 µM and 6 µM standards (1 µM  
and 3 µM) in the 2.5 µl injected volume, we would calculate there to 
be 5 pmol of that metabolite in the standard amount of Fleischmann’s 
extract that will be used for all subsequent samples.  This 
determination is made in technical replicates.  Importantly, we cannot 
expect the 5 pmol peak area of that metabolite to remain constant 
when Fleischmann’s extract is mixed with experimental yeast extracts 
because peak shapes are often distorted, and ionization is suppressed 
due to sample complexity.  However, because the 13C metabolites in 
Fleischmann’s extract will have the same degree of ionization 
suppression as the 12C metabolites in the experimental extract, the 
peak area ratios of 12C to 13C metabolites and the known mol amounts 
of the Fleischmann’s metabolites allow calculation of the amounts of 
the experimental metabolites.  Molar calculation of the Fleischmann’s 
metabolites are not performed.  Mol amounts of metabolites in the 
experimental samples are converted to molar using the calculation of 
intracellular volume described above.  Because the IMP peak in 
Fleischmann’s extract is quite small, we use relative peak areas of IMP 
and NMN in the standard solutions to derive a correction factor that 
allows IMP in experimental samples to be quantified against the 
Fleischmann’s NMN peak.  For each metabolite, the peak area used 
for quantification is that of the MS2 transition. 
In theory, inclusion of 1.5 µM 18O labeled Nam and 18O labeled 
NR should be sufficient to quantify nonlabeled Nam and NR in the 
experimental extracts.  In practice, because label incorporation may 
vary and there is greater accuracy in preparation of 10 mM standards 
than 1.5 µM radiolabeled standards, we quantify the 18O peaks of 
Nam and NR against a standard curve of NA, Nam and NR.  These 
analyses result in a mol amount of heavy Nam and NR determined 
from the light standards.  Because the same amount of heavy Nam 
and NR will be in all experimental samples, relative peak areas allow 
conversion of experimental Nam and NR peaks to mol and molar.  
The peak area ratio between heavy Nam and NA in the standard 
solutions is used to derive a correction factor that allows the heavy 
Nam peak to calculate the amount of NA in experimental samples. 
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Figure 2. Chromatograms of all 19 metabolites generated from injection of complex standard solutions using MRM LC-MS.  All compounds were detected in 
positive ion mode in alkaline (A) and acidic (B) separations.  Multiple peaks observed in Uridine and NA illustrate cross talk from other metabolites in mixture.  
In the case of Uridine, the early eluting peak is the result of the 13C peak of Cytidine.  NA later eluting peaks are the result of 13C peaks from Nam produced 
either from the Nam standard or on-source fragmentation of NR to Nam. 
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Earlier, we described an assay of the NAD+ metabolome based on 
hydrophilic interaction liquid chromatography [3].  Encouraged by its 
track record for separation of nucleosides and nucleotides [52-54], we 
have since developed an improved separation with the porous 
graphitic carbon reversed phase material, Hypercarb (Thermo).  
Resolution of all compounds is done with two different mobile 
phases on two Hypercarb columns, each used solely for one 
separation. 
 
 
In the alkaline separation, solvent A is 7.5 mM ammonium acetate 
with 0.05% (v/v) ammonium hydroxide and solvent B is 0.05% 
(v/v) ammonium hydroxide in acetonitrile.  The optimized gradient 
is described in Table 1 with a flow rate of 0.08 ml/min and a column 
temperature of 60 °C.  As shown in Table 1, the complete run takes 
32.2 min on a 1 mm x 100 mm Hypercarb column and must be 
equilibrated for 20 min prior to first injection.  
In the acid separation, solvent A is 10 mM ammonium acetate 
with 0.1% formic acid and solvent B is 0.1% formic acid in 
acetonitrile.  The optimized gradient is described in Table 2 with a 
flow rate of 0.2 mL/min and a column temperature of 60 °C.  As 
shown in Table 2, the complete run takes 23.4 min on a 2.1 mm x 
100 mm Hypercarb column.  Extracted ion currents for each resolved 
metabolite are provided in Figure 2. 
 
 
The power of triple quadrupole mass spectrometers is the ability 
to perform multiple SRM protocols in a single run, i.e. multiple 
reaction monitoring (MRM).  Modern QQQs , such as the Waters 
Acquity TQD employed herein, are equipped with automatic 
optimization software to detect transitions and optimize ionization. 
The software can be the best friend and greatest enemy in method 
development.  Since many of the metabolites are of similar structure 
and mass, specific diagnostic fragments must be identified and 
optimized.  The carboxylic acid versus carboxamide metabolites and 
the oxidized versus reduced metabolites differ by only one Dalton.  
The 13C peaks produced from metabolites such as NAD+ and 
NADP+ would produce crosstalk with NADH and NADPH, 
respectively (Figure 2A).  However, all four compounds produce 
diagnostic fragments, allowing for specific quantification.  Current 
automatic optimization software identifies fragments that are most 
easily produced and not necessarily those that are diagnostic for the 
metabolite in the context of structural similarities in the NAD+ 
metabolome.  Online searchable libraries such as Metlin 
(http://metlin.scripps.edu/) and Massbank 
(http://www.massbank.jp/?lang=en) provide MS/MS spectra for 
many metabolites with identified fragment structures [55,56].  
Specific fragments for NADH and NADPH not identified by the 
automatic software were chosen based on these searches.  The 
transitions were optimized manually.  Transitions and optimized 
conditions are detailed in Table 1. 
The cone voltage must be optimized when measuring NAD+ 
especially for NR, NAR, NAMN, and NMN to reduce on-source 
fragmentation.  NR and NMN readily produce Nam signal, whereas 
NAR and NAMN produce NA signal (Figure 2B, Nam extracted ion 
current). Optimization of cone voltage decreases but does not 
completely remove crosstalk. This unavoidable crosstalk greatly 
illustrates the need for robust LC separation. 
After development, overall robustness was determined based on 
the capacity factors (k’), quantitative range, linear goodness of fit 
(R2), replicative standard deviation (RSD) of the method, and RSD 
of the system. Capacity factors were above 2 for all analytes with the 
exception of CMP (k’ = 1) (Table 1). Standard curves were linear 
from 0.125 picomoles to 250 picomoles with R2 values falling above 
0.99 for all but NAR (0.948), inosine (0.974), NR (0.981) and 
NADH (0.988).  RSD of the method was measured with six separate 
standard solutions at 10 µM concentrations.  RSD of the system was 
measured with four injections of the same standard solution.  Method 
RSDs were below 10% for all but cytidine, NAR, inosine, NAMN, 
ATP, NAAD, NADH, and NADP.  System RSDs were below 10% 
for all but cytidine and NAR.  Limits of quantification (LOQ) were 
measured empirically and defined as the concentration producing a 
signal-to-noise ratio of 10.  LOQ were below 100 fmol for all but 
NMN (1 pmol), ATP (1 pmol), NA (2.5 pmol), and uridine (3.1 
pmol).  Moreover, the LOQ using this method was at least 3-fold 
lower for seven metabolites than the previously used method.  The 
previous method is 3-fold more sensitive for one metabolite (Table 3) 
[3]. 
 
 In our hands, AMP and NADPH cannot be reliably quantified 
by these methods.  ATP and ADP fragment on source to AMP, 
similar to NR fragmentation to Nam (Figure 2B Nam extracted ion 
current). Given poor resolution of AMP from both metabolites, 
detected AMP signal would represent biological AMP as well as that 
derived from ATP and ADP.  Further, the NADP peak may represent 
the sum of cellular NADP and a portion of cellular NADPH, which 
has become oxidized.  Thus, care should be taken in interpreting the 
NADP peak. 
Nam is strikingly membrane permeable.  Nam in cells can be 
easily lost into post-cellular supernatants and we suspect that Nam in 
organelles can be easily lost into post-organelle supernatants. 
LCMS-based Metabolomics 
Volume No: 4, Issue: 5, January 2013, e201301012 Computational and Structural Biotechnology Journal | www.csbj.org 
6 
To test our method on a real sample, we analyzed a glioma cell 
line, LN428/MPG (a gift of Dr. Robert Sobol, University of 
Pittsburgh), which had been grown in MEMalpha (10% FBS HI, 
gentamycin, geneticin) media in triplicate 150 mm dishes (2 x 107 
cells per dish by CASY cell count).  The results of the analysis are 
reported in Table 4.  As expected, nucleotides, such as ATP, ADP, 
UMP, and NAD+, are high in abundance compared to NAD+ 
precursors and biosynthetic intermediates.  The NAD+:NADH ratio 
is ~39 and the NAD+:NADP ratio is 4.6.  As expected for cells 
grown in a type of Dulbecco’s modified Eagle’s media, Nam but not 
other vitamins is detectable.  The concentration of NMN is low when 
compared with yeast, suggesting the NMN pool is converted rapidly 
to NAD+ [3]. 
Conclusions 
 
Here, an improved LC-MS method has been developed to 
quantify the NAD+ metabolome.  Its principle features are resolution 
and quantification of 16 metabolites in an alkaline separation, and 
resolution and separation of 3 metabolites in an acidic separation, 
both on a porous graphitic carbon stationary phase.  The problem of 
ionization suppression that plagued earlier methods has been 
eliminated.  Preservation and quantification of NADPH remains a 
challenge. 
LCMS-based Metabolomics 
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